Measures of Response in Clinical Trials of Systemic Sclerosis: The Combined Response Index for Systemic Sclerosis (CRISS) and Outcome Measures in Pulmonary Arterial Hypertension Related to Systemic Sclerosis (EPOSS)

REFERENCES

1. 1.↵
   1. Furst DE,
   2. Khanna D,
   3. Mattuci-Cerinic M,
   4. Silman AJ,
   5. Merkel PA,
   6. Foeldvari I

   . Scleroderma – developing measures of response. J Rheumatol 2005;32:2477–80.

   OpenUrlAbstract/FREE Full Text
2. 2.↵
   1. Steen VD,
   2. Medsger TA

   . Changes in causes of death in systemic sclerosis, 1972–2002. Ann Rheum Dis 2007;66:940–4.

   OpenUrlAbstract/FREE Full Text
3. 3.↵
   1. Merkel PA,
   2. Clements PJ,
   3. Reveille JD,
   4. Suarez-Almazor ME,
   5. Furst D,
   6. et al.

   Current status of outcome measure development for clinical trials in systemic sclerosis. J Rheumatol 2003;30:1630–47.

   OpenUrlAbstract/FREE Full Text
4. 4.↵
   1. Khanna D,
   2. Hays RD,
   3. Park GS,
   4. Braun-Moscovici Y,
   5. Mayes MD,
   6. McNearney TA,
   7. et al.

   Development of the Scleroderma Gastrointestinal Tract 1.0 (SSc-GIT 1.0) quality of life instrument—preliminary report [abstract]. Arthritis Rheum 2006;54 Suppl:S479.

   OpenUrl
5. 5.↵
   1. Kissin EY,
   2. Schiller AM,
   3. Gelbard RB,
   4. Anderson JJ,
   5. Falanga V,
   6. Simms RW,
   7. et al.

   Durometry for the assessment of skin disease in systemic sclerosis. Arthritis Rheum 2006;55:603–9.

   OpenUrlCrossRefPubMed
6. 6.↵
   1. White B,
   2. Bauer EA,
   3. Goldsmith LA,
   4. Hochberg MC,
   5. Katz LM,
   6. Korn JH,
   7. et al.

   Guidelines for clinical trials in systemic sclerosis (scleroderma). I. Disease-modifying interventions. The American College of Rheumatology Committee on Design and Outcomes in Clinical Trials in Systemic Sclerosis. Arthritis Rheum 1995;38:351–60.

   OpenUrlPubMed
7. 7.↵
   1. Charles C,
   2. Clements P,
   3. Furst DE

   . Systemic sclerosis: hypothesis-driven treatment strategies. Lancet 2006;367:1683–91.

   OpenUrlCrossRefPubMed
8. 8.↵
   1. Varga J

   . Scleroderma and Smads: dysfunctional Smad family dynamics culminating in fibrosis. Arthritis Rheum 2002;46:1703–13.

   OpenUrlCrossRefPubMed
9. 9.↵
   1. Varga J

   . Antifibrotic therapy in scleroderma: extracellular or intracellular targeting of activated fibroblasts? Curr Rheumatol Rep 2004;6:164–70.

   OpenUrlPubMed
10. 10.↵
    1. Clements P,
    2. Lachenbruch P,
    3. Siebold J,
    4. White B,
    5. Wiener S,
    6. Martin R,
    7. et al.

    Inter and intraobserver variability of total skin thickness score (modified Rodnan TSS) in systemic sclerosis. J Rheumatol 1995;22:1281–5.

    OpenUrlPubMed
11. 11.↵
    1. Clements PJ,
    2. Hurwitz EL,
    3. Wong WK,
    4. Seibold JR,
    5. Mayes M,
    6. White B,
    7. et al.

    Skin thickness score as a predictor and correlate of outcome in systemic sclerosis: high-dose versus low-dose penicillamine trial. Arthritis Rheum 2000;43:2445–54.

    OpenUrlCrossRefPubMed
12. 12.↵
    1. Felson DT,
    2. Anderson JJ,
    3. Boers M,
    4. Bombardier C,
    5. Furst D,
    6. Goldsmith C,
    7. et al.

    American College of Rheumatology. Preliminary definition of improvement in rheumatoid arthritis. Arthritis Rheum 1995;38:727–35.

    OpenUrlPubMed
13. 13.↵
    1. Singh JA,
    2. Solomon DH,
    3. Dougados M,
    4. Felson D,
    5. Hawker G,
    6. Katz P,
    7. et al.

    Development of classification and response criteria for rheumatic diseases. Arthritis Rheum 2006;55:348–52.

    OpenUrlCrossRefPubMed
14. 14.↵
    1. Giannini EH,
    2. Ruperto N,
    3. Ravelli A,
    4. Lovell DJ,
    5. Felson DT,
    6. Martini A

    . Preliminary definition of improvement in juvenile arthritis. Arthritis Rheum 1997;40:1202–9.

    OpenUrlPubMed
15. 15.↵
    1. Distler O,
    2. Behrens F,
    3. Huscher D,
    4. Foeldvari I,
    5. Zink A,
    6. Nash P,
    7. et al.

    Need for improved outcome measures in pulmonary arterial hypertension related to systemic sclerosis. Rheumatology 2006;45:1455–7.

    OpenUrlFREE Full Text
16. 16.↵
    1. Distler O,
    2. Behrens F,
    3. Pittrow D,
    4. Huscher D,
    5. Denton CP,
    6. Foeldvari I,
    7. et al.

    Defining appropriate outcome measures in pulmonary arterial hypertension related to systemic sclerosis: a Delphi consensus study with cluster analysis. Arthritis Rheum 2008;15:867–75.

    OpenUrl
17. 17.↵
    1. Allanore Y,
    2. Meune C,
    3. Avouac J,
    4. Wipff J,
    5. Mouthon L,
    6. Guillevin L,
    7. et al.

    Cardiac involvement in systemic sclerosis assessed by tissue-doppler echocardiography in routine care: a controlled study of 100 consecutive patients [abstract]. Ann Rheum Dis 2008;67 Suppl II: 361 [FRI0241]

    OpenUrl
18. 18.↵
    1. Avouac J,
    2. Wipff M,
    3. Kahan A,
    4. Allanore Y

    . Effects of new oral treatments on exercise capacity in connective tissue disease related pulmonary arterial hypertension: a meta-analysis of randomized controlled trials [abstract]. Ann Rheum Dis 2008;67 Suppl II:361 [FRI0242]

    OpenUrl
19. 19.
    1. Khanna D,
    2. Lovell DJ,
    3. Giannini E,
    4. Clements PJ,
    5. Merkel PA,
    6. Seibold JR,
    7. et al.

    Development of a provisional core set of response measures for clinical trials of systemic sclerosis. Ann Rheum Dis 2008;67:703–9.

    OpenUrlAbstract/FREE Full Text